Advertisement


Roy S. Herbst, MD, PhD, on Results From SWOG S0819

2015 IASLC World Conference on Lung Cancer

Advertisement

Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).



Related Videos

Lung Cancer

Guneet Walia, PhD, on Central Issues in Lung Cancer Care

Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.

Lung Cancer
Symptom Management

Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials

Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).

Lung Cancer

Ugo Pastorino, MD, on Reducing Lung Cancer Mortality

Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening (Abstract PLEN04.07).

Lung Cancer

Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial

Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).

Lung Cancer

Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors

Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.

Advertisement

Advertisement




Advertisement